SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Carl Zeiss Meditec AG CZMWY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • DE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Carl Zeiss Meditec AG (CZMWY) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $31.85. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $2.2B, +5.5%/yr average growth. Net income is $141M, growing at -20.2%/yr. Net profit margin is 6.3% (thin). Gross margin is 52.8% (-6.5 pp trend).

Balance sheet: total debt is $132M against $2.5B equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 2.77 (strong liquidity). Debt-to-assets is 3.3%. Total assets: $4.1B.

Analyst outlook: 1 / 4 analysts rate CZMWY as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 59/100 (Partial), Future 20/100 (Fail), Income 45/100 (Partial).

CZMWY SharesGrow Score Overview

60/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 59/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CZMWY

CZMWY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CZMWY: +5.5%/yr revenue is, -20.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CZMWY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CZMWY: Debt-to-Equity (D/E) ratio 0.05 (conservative), Current ratio is 2.77 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CZMWY: Gross margin is 52.8% (-6.5 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 59/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 4 analysts rate CZMWY as buy (25%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CZMWY: Net profit margin is 6.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range26.65-75.01

Volume3.26K

Avg Volume (30D)5.88K

Market Cap$2.79B

Beta (1Y)1.34

Dividend Yield$0.4081

Share Statistics

EPS (TTM)1.52

Shares Outstanding$87.54M

IPO Date2012-08-03

Employees2,066

CEOAndreas Pecher

Financial Highlights & Ratios

Revenue (TTM)$2.23B

Gross Profit$1.18B

EBITDA$346.89M

Net Income$141.21M

Operating Income$223.32M

Total Cash$27.27M

Total Debt$132.46M

Net Debt$105.19M

Total Assets$4.06B

Price / Earnings (P/E)21

Price / Sales (P/S)1.25

Analyst Forecast

Rating ConsensusHold

Analysts Covering4

Buy 25% Hold 50% Sell 25%

Company Info

CountryDE

ExchangeOther OTC

CurrencyUSD

ISINUS14218T1051

Price Chart

CZMWY

Carl Zeiss Meditec AG ↗ · Other OTC

Healthcare • Medical - Instruments & Supplies

26.65 52WK RANGE 75.01

People Also View

EssilorLuxottica SA

HOYA Corporation

West Pharmaceutical Services, Inc.

Straumann Holding AG

The Cooper Companies, Inc.

Baxter International Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message